Clinical practice guidelines for PSA testing and early management of test-detected prostate cancer
Guidelines developed in partnership with
This resource has been developed, reviewed or revised more than five years ago. It may no longer reflect current evidence or best practice.
Published: 2015
National Health and Medical Research Council
Note: Please note that the relevant excerpt pages of the technical report are accessible in the appendix of each content page.
Introduction
1 Risk
2 Testing
2.1. Decision support for men considering PSA testing
2.3. Role of digital rectal examination
2.4. PSA testing and life expectancy
2.5. Testing with variants of PSA to improve sensitivity after an initial total PSA ≤ 3.0 ng/mL
3 Prostate biopsy and multiparametric MRI
3.2. Follow-up to a negative prostate biopsy
4 Active surveillance
5 Watchful waiting
6 Sociocultural aspects of PSA Testing in Australia
Appendices
Appendix 1 Guideline development process
Appendix 2 Committee members and contributors
Appendix 3 List of clinical questions
Appendix 4 TNM classification of prostate tumours